mRNA (messenger ribonucleic acid) vaccines are a type of vaccine that uses synthetic mRNA molecules to teach the body’s cells how to make a specific protein found on a pathogen.
Messenger RNA (mRNA) vaccines use synthetic mRNA to instruct human cells to produce harmless antigens that trigger an immune response.
The immune system recognizes this protein as foreign and produces antibodies and other immune cells to fight it off, building protection against future infection.
mRNA vaccines work at a cellular level.
mRNA vaccines are injected, typically into the upper arm muscle.
Tiny fatty droplets called lipid nanoparticles (LNPs) encapsulate the mRNA to protect it from degradation and help it enter the cells.
When inside the muscle cells and other antigen-presenting cells (APCs), the mRNA acts as a blueprint, using the cell’s ribosome machinery to produce copies of the specific protein (e.g., the SARS-CoV-2 spike protein).
As a cell displays this harmless protein piece on its surface the immune system detects the foreign protein and begins to generate a targeted response, including producing antibodies and activating T-cells.
The synthetic mRNA from the vaccine is quickly broken down and removed by the body’s natural cellular processes within a few days.
The body is left with long-lasting immune memory, ready to respond quickly if exposed to the actual virus in the future.
A primary advantage is the rapid manufacturing process.
When the genetic sequence of a pathogen is known, the corresponding mRNA vaccine can be designed and produced much faster than traditional vaccines, which often require growing large amounts of the virus in cell cultures or eggs.
Unlike traditional vaccines, mRNA vaccines do not contain any live, weakened, or inactive virus, so they cannot cause the disease they are designed to prevent, making them safer and faster to develop.
Delivery: mRNA is encapsulated in lipid nanoparticles (LNPs) for protection from degradation and efficient uptake by cells, typically via intramuscular injection.
The mRNA also does not enter the cell’s nucleus and cannot alter a person’s DNA.
Once inside cells, mRNA enters the cytoplasm and uses the cell’s ribosomes to produce a target antigen-the SARS-CoV-2 spike protein).
Immune Activation: The antigen is displayed on the cell surface, alerting the immune system.
This stimulates B cells to produce antibodies and T cells for longer-term protection.
The mRNA degrades naturally within days, leaving no permanent genetic changes.
mRNA vaccines can induce both humoral (antibody) and cellular immunity, offering robust protection.
Advantages of mRNA vaccines are rapid design based on genetic sequences, scalable manufacturing, and adaptability to variants.
The platform is highly adaptable, allowing researchers to quickly update the genetic sequence to target new variants or different diseases.
The only authorized or approved mRNA vaccines are those for COVID-19 (Pfizer-BioNTech and Moderna).
mRNA technology is leading to potential vaccines for a wide range of other infectious diseases and conditions, many of which are currently in clinical trials:
Influenza vaccines Zika, rabies, and cytomegalovirus (CMV) HIV, Hepatitis C, and Herpes simplex virus 2 (genital herpes)
Cancer therapeutic vaccines to help the immune system target specific cancer cells Genetic disorders
COVID-19: Phase 3 trials showed 90-95% protection against symptomatic infection and near-100% against hospitalization/death for original strains.
Efficacy wanes against infection with variants (e.g., 60-80% for Delta/Omicron), but boosters restore high protection (80-95%) against severe outcomes.
Preclinical/clinical data support 80-100% efficacy in animal models for influenza, Zika, rabies, and RSV.
In cancer trials, mRNA vaccines (e.g., personalized neoantigen vaccines) induce tumor-specific T-cell responses, with response rates up to 40% in melanoma.
mRNA vaccines are generally safe, with billions of doses administered globally.
Most side effects are mild and short-lived:
Common (10-50% of recipients): Injection-site pain, fatigue, headache, muscle pain, chills—more pronounced after the second dose.
Rare/Serious (<0.01%): Myocarditis/pericarditis (mostly in young males, 1-10 per 100,000 doses; resolves quickly), anaphylaxis (2-5 per million doses).
No evidence of fertility issues, DNA alteration, or increased long-term risks like cancer.
Monitoring: Post-approval data (e.g., VAERS, WHO) confirm benefits outweigh risks, especially for high-risk groups.
Long-term studies (up to 4+ years) show sustained safety.
COVID-19 Boosters: Bivalent/updated monovalent formulations target variants like JN.1 and KP.2, with 70-85% efficacy against infection and >90% against hospitalization.
Infectious Diseases: Phase 3 trials for seasonal flu (Moderna mRNA-1010, ~75% efficacy), RSV (mRNA-1345, 80-90% in older adults), and HIV (personalized immunogens).
Dengue vaccine (mRNA-1944) shows promise against serotypes 1-3.
Individualized mRNA vaccines (e.g., Moderna’s mRNA-4157 with Keytruda) in Phase 3 for melanoma (44% risk reduction in recurrence).
Early trials for pancreatic cancer and glioblastoma.
Emerging uses in regenerative medicine (e.g., protein replacement for genetic disorders).